Isolation of Pancreatic Islets by FACS

糖尿病影响着全世界超过1.5亿人。使用胰岛素或旨在克服导致疾病的代谢缺陷的药物治疗通常成功有限，因为它们不能治愈疾病。胰腺移植已被成功地应用，但胰腺的胰岛成分仅占整个胰腺的一小部分，约为1%。最近，埃德蒙顿小组成功地使用了胰岛移植。然而，目前的胰岛移植已成功地用于埃德蒙顿组。然而，目前的胰岛纯化限制了可以处理的数量，并导致制备物在产量、活力和功能性方面不一致。本文提出通过荧光激活细胞分选（FACS）来纯化胰岛。FACS领域的新进展将允许大大增加高度纯化的胰岛的产量和活性。新胰岛制剂的更大数量和更高活性将导致更成功和更持久的胰岛移植。拟议的商业应用：我们建议建立一个系统，用于分选和纯化胰岛用于胰岛为基础的研究和移植。该系统将提供更高的质量、更高的产量，并且将比当前获得/分选胰岛的方法更具成本效益。胰岛生产的应用将是糖尿病及其相关疾病。这里提出的方法是可申请专利的，并将具有巨大的商业价值，为技术许可和分配的胰岛。

Diabetes affects more than 150 million people worldwide. Treating using insulin or drugs designed to overcome metabolic deficiencies causing the disease often have limited success since they do not cure the disease. Pancreatic transplantation have been used successfully, but the islet component of the pancreas is a small part of the total pancreas perhaps 1%. Recently, islet transplantation has been used successfully by the Edmonton group. However, current islet transplantation has been used successfully by the Edmonton group. However, current islet purification limits the numbers that can be treated and results in preparations that are inconsistent in yield, viability and functionality. It is here proposed to purify islets by fluorescence-activated cell sorting (FACS). New advances in the area of FACS will allow for greatly increased yield and activity of the highly purified islets. The greater quantity and greater activity of the new islet preparations will result in more successful and long-lasting islet transplantations. PROPOSED COMMERCIAL APPLICATIONS: We propose to establish a system for sorting and purifying islets to be used in islet-based research and transplantation. This system will provide a higher quality, higher yield, and will be more cost effective than the current methods of obtaining/sorting islets. The application for islet production would be for diabetes and its related afflictions. The method proposed here is patentable and will be of substantial commercial value for licensing for the technology and distributing the islets.